LV009 injection
Relapsed/Refractory CD19-positive hematologic malignancies
Clinical Trial (phase not specified)Active (patient recruitment)
Key Facts
Indication
Relapsed/Refractory CD19-positive hematologic malignancies
Phase
Clinical Trial (phase not specified)
Status
Active (patient recruitment)
Company
About PersonGen BioTherapeutics
A Chinese biotech company developing next-generation CAR-T and allogeneic cellular therapies for T-cell cancers and autoimmune diseases.
View full company profile